Drug Trial Radar · NCT04108195
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
290
Actual
Start
Feb 21, 2020
Primary completion
Apr 7, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Participants will receive daratumumab.
TalquetamabDrug
Participants will receive talquetamab.
TeclistamabDrug
Participants will receive teclistamab.
PomalidomideDrug
Participants will receive pomalidomide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 52 Weeks
- Part 1: Number of Participants With Dose Limiting Toxicity by SeverityTime frame: Up to 52 Weeks
- Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 48 Weeks
- Part 2: Number of Participants With Adverse Events and SAEs by SeverityTime frame: Up to 48 Weeks
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California
University of California San Francisco
San Francisco, California
The Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, New York
Mount Sinai Medical Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Medical College Of Wisconsin
Milwaukee, Wisconsin
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
University Health Network UHN Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Universitatsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Universitatsklinikum Wurzburg
Würzburg, Germany
VU Medisch Centrum
Amsterdam, Netherlands
LUMC
Leiden, Netherlands
Hosp Clinic de Barcelona
Barcelona, Spain
Inst. Cat. Doncologia-H Duran I Reynals
Barcelona, Spain
Germans Trias I Pujol
Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
Clinica Univ. de Navarra
Pamplona, Spain
Hosp Clinico Univ de Salamanca
Salamanca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.